Injectable thyroid medication
Pro Research Analysisby 
Searched over 200M research papers
Injectable Thyroid Medication: Current Research and Applications
Percutaneous Ethanol Injection Therapy (PEIT) for Thyroid Nodules
Efficacy of PEIT in Benign Thyroid Nodules
Percutaneous ethanol injection therapy (PEIT) has been extensively studied for its effectiveness in treating benign solitary solid cold thyroid nodules. Research indicates that PEIT can significantly reduce nodule volume and alleviate symptoms. In a randomized clinical trial, a single intranodular injection of sterile 98% ethanol resulted in a median reduction in nodule volume of 47%, compared to just 9% in patients treated with suppressive doses of L-thyroxine (L-T4) . Another study comparing one injection with three injections of ethanol found that both regimens effectively reduced nodule volume by approximately 46-51% over six months, although the additional doses did not significantly enhance the outcome .
PEIT for Autonomous Thyroid Nodules
PEIT has also been evaluated for autonomously functioning thyroid nodules. An Italian multicenter study involving 429 patients demonstrated that PEIT successfully normalized thyroid hormone levels and reduced nodule size in 66.5% of patients with toxic adenoma and 83.4% of those with pretoxic adenoma . These results suggest that PEIT is a viable alternative to surgery and radioiodine therapy, particularly for smaller nodules.
Long-Term Efficacy and Safety
Long-term studies have shown that PEIT can provide sustained relief from symptoms and significant nodule shrinkage. A five-year follow-up study reported a 91.9% reduction in nodule volume, with no significant regrowth observed after six months . However, the procedure can be painful, and side effects such as transient thyrotoxicosis, facial dysesthesia, and paranodular fibrosis have been noted Bennedbæk1999Bennedb1997.
Subcutaneous Injection of Recombinant Human Thyrotropin (rhTSH)
Alternative to Thyroid Hormone Withdrawal
For patients with thyroid cancer who are on anticoagulants, subcutaneous (SC) injections of recombinant human thyrotropin (rhTSH) offer a safer alternative to intramuscular (IM) injections, which carry a risk of hematoma. Preliminary results indicate that SC administration of rhTSH effectively increases serum TSH levels without adverse effects, making it a viable option for monitoring thyroid cancer patients .
Subcutaneous Injection of Somatostatin Analogue (SMS 201-995)
Impact on Thyroid-Stimulating Hormone (TSH)
The synthetic analogue of somatostatin, SMS 201-995, has been shown to suppress TSH secretion in normal subjects. A study involving subcutaneous injections of SMS demonstrated a dose-dependent suppression of plasma TSH levels, lasting for at least eight hours post-injection . This suggests potential applications in conditions where TSH suppression is desired.
Conclusion
Injectable therapies for thyroid conditions, particularly PEIT and subcutaneous injections of rhTSH and somatostatin analogues, show promising results in reducing nodule size, normalizing hormone levels, and providing symptom relief. While PEIT is effective for both benign and autonomously functioning thyroid nodules, its painful nature and potential side effects necessitate careful consideration. Subcutaneous rhTSH injections offer a safer alternative for thyroid cancer patients on anticoagulants. Further research and long-term studies are needed to optimize these treatments and confirm their efficacy and safety.
Sources and full results
Most relevant research papers on this topic